Alto Neuroscience Reports Q3 2026 Net Loss of $25.1 Million; Cash Runway Through 2030

Alto Neuroscience reported a third-quarter 2026 net loss of $25.1 million, compared with $14.2 million a year earlier, as research and development and general and administrative expenses increased. Cash, cash equivalents and restricted cash totaled $319.8 million at September 30, and the company ex…